大麻（及其他药物）的合理管制表尚不存在

Under US law and international treaties, drug scheduling is a multiple-choice problem for which the answer that would often be best is not an option David Pozen1 and Matthew Lawrence2 I n the process currently underway to reconsider the status of marijuana under US law, many have urged the Drug Enforce- ment Administration (DEA) to engage in rigorous, evidence- based policy-making. But the agency’s choices about how to regulate marijuana are sharply—and irrationally—constrained by the Controlled Substances Act (CSA) and its menu of drug “sched- ules.” These schedules often force regulators into a Hobson’s choice be- tween overcriminalizing drugs, through prohibitions that predictably backfire, or overcommercializing drugs, through hands-off approaches that leave users vulnerable to corporate exploitation. …